Dr. Johnson on the Limitations of Biomarkers in Melanoma

Source: OncLive, August 2020

Douglas B. Johnson, MD, MSCI, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses the limitations of biomarkers in melanoma.

Identifying novel biomarkers in melanoma has been a challenging area of research, says Johnson.

Initially, PD-L1 expression was evaluated as a way to determine whether patients should receive single-agent PD-1 inhibitors or the combination of PD-1 plus CTLA-4 inhibitors, Johnson explains.

READ THE ORIGINAL FULL ARTICLE